Effects of Vasopressin on Sweat Rate and Composition in Patients with Diabetes Insipidus and Normal Controls

Baseline sweat rate and concentrations of sodium, chloride, and potassium, and the effect of exogenous vasopressin on these parameters were determined in 13 patients with acquired diabetes insipidus (ADI), four patients with nephrogenic diabetes insipidus (NDI), three subjects with cystic fibrosis, and age- and sex-matched controls. The four patients with NDI did not differ from the controls with respect to baseline sweat rate, but baseline sodium, chloride, and potassium concentrations were significantly elevated. In addition, parenteral vasopressin caused a significant decrease in sweat rate (p < .01) while the electrolyte concentrations remained unchanged. This indicates that vasopressin may also have an effect on electrolyte reabsorption in NDI patients. Alternatively, the amount of sweat precursor fluid may have been reduced. The patients with ADI did not differ from the controls with respect to baseline data, and parenteral vasopressin had no effect on their sweat rate and composition. Likewise, vasopressin had no effect in controls or patients with cystic fibrosis. We conclude that, except in patients with NDI, vasopressin does not play a significant role in the regulation of human eccrine sweating. Sweat gland physiology appears to be different in patients with NDI and in them vasopressin may have a significant effect on sweat

Dynamic Reflectarray Technology for Electro-Optical Sensors

An array of two or more tunable electro-optical reflecting elements where the phase response of one to more elements may be adjusted by a variety of approaches including, but not limited to a liquid crystal superstrate, schottky contact(s), ultra-violet radiation pulses, and illumination of photoconductive substances. Methods and apparatus for direct and/or adaptive control of phase response via the above approaches are also discussed

Global clinical response in C ushing's syndrome patients treated with mifepristone

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106755/1/cen12332.pd

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

PurposeAdvanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines.MethodsThe anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn(®)).ResultsBelinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21(Waf), and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro.ConclusionsIn summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer

Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Background: Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women

Systematic Genetic Nomenclature for Type VII Secretion Systems

CITATION: Bitter, W., et al. 2009. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathogens, 5(10): 1-6, doi: 10.1371/journal.ppat.1000507.The original publication is available at http://journals.plos.org/plospathogensMycobacteria, such as the etiological agent of human tuberculosis, Mycobacterium tuberculosis, are protected by an impermeable cell envelope composed of an inner cytoplasmic membrane, a peptidoglycan layer, an arabinogalactan layer, and an outer membrane. This second membrane consists of covalently linked, tightly packed long-chain mycolic acids [1,2] and noncovalently bound shorter lipids involved in pathogenicity [3–5]. To ensure protein transport across this complex cell envelope, mycobacteria use various secretion pathways, such as the SecA1-mediated general secretory pathway [6,7], an alternative SecA2-operated pathway [8], a twin-arginine translocation system [9,10], and a specialized secretion pathway variously named ESAT-6-, SNM-, ESX-, or type VII secretion [11–16]. The latter pathway, hereafter referred to as type VII secretion (T7S), has recently become a large and competitive research topic that is closely linked to studies of host–pathogen interactions of M. tuberculosis [17] and other pathogenic mycobacteria [16]. Molecular details are just beginning to be revealed [18–22] showing that T7S systems are complex machineries with multiple components and multiple substrates. Despite their biological importance, there has been a lack of a clear naming policy for the components and substrates of these systems. As there are multiple paralogous T7S systems within the Mycobacteria and orthologous systems in related bacteria, we are concerned that, without a unified nomenclature system, a multitude of redundant and obscure gene names will be used that will inevitably lead to confusion and hinder future progress. In this opinion piece we will therefore propose and introduce a systematic nomenclature with guidelines for name selection of new components that will greatly facilitate communication and understanding in this rapidly developing field of research.http://journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat.1000507Publisher's versio